Cellesce has developed a new bioprocessing technology for the growing and expansion of organoids. Our process yields high quality organoids, with low batch-to-batch variation – in the quantities required for commercial use.
Cellesce is building a range of colorectal cancer organoids for applications in drug discovery. This will be our first commercial offer, and will launch in mid 2017.
We will then add organoids from other tissues to our product range.
Revolutionising Cancer Drug Discovery
Organoid models are a powerful new enabling technology in cancer drug discovery. Because organoids are closer to in vivo tissue structure than other available models, they give more accurate responses to drug candidates. Using organoids in drug discovery assays, pharmaceutical companies can pick ‘winners’ earlier and weed out ‘losers’ before incurring high development costs.
Cellesce is expert in bioprocessing and 3D cell culture including the growing and expansion of organoids. We can assist with the design and development of bioreactors and peripheral systems for a variety of use cases. Please contact us for further information.
3D bioprocessing capability
The Cellesce team comprises experts in biochemical engineering, bioreactors and associated technologies. We use this capability to build scalable processes to take new therapies from the laboratory to the clinic.
Cellesce is leveraging the output of research programmes and associated capability at University of Bath and Cardiff University. This research is currently focused on organoids which provide a powerful new approach to high throughput drug screening and could ultimately be used in personalised medicine.
Organoid processing technology
Cellesce has built a scalable (patent pending) process for the expansion of organoids. Organoids are 3D cell structures grown from stem cells with organ-like characteristics that retain multiple features of normal and diseased tissues. We are exploring opportunities to deploy this technology across a range of applications.